Eli Lilly

Court tosses kickbacks case against Eli Lilly but allows plaintiffs another chance
Court tosses kickbacks case against Eli Lilly but allows plaintiffs another chance
Fierce Pharma
Eli Lilly
whistleblowers
kickbacks
Humalog
Humulin
Forteo
Flag link:
Accelerator Life Science Partners Launch Startup With $31 Million Series A
Accelerator Life Science Partners Launch Startup With $31 Million Series A
CP Wire
Eli Lilly
Pfizer Ventures
JNJ Ventures
AbbVie Ventures
Accelerator Life Science Partners
Magnolia Neurosciences Corporation
Flag link:
Elanco’s IPO Would Free Eli Lilly to Focus on Pharmaceuticals
Elanco’s IPO Would Free Eli Lilly to Focus on Pharmaceuticals
Xconomy
Elanco
Eli Lilly
animal health
IPOs
Flag link:
Drugmaker Lilly's Elanco animal health unit files for IPO
Drugmaker Lilly's Elanco animal health unit files for IPO
Yahoo/Reuters
Elanco
animal health
Eli Lilly
IPOs
Flag link:
Karuna raises $42M to resurrect abandoned Lilly drug for schizophrenia
Karuna raises $42M to resurrect abandoned Lilly drug for schizophrenia
Fierce Biotech
Karuna Pharmaceuticals
Eli Lilly
schizophrenia
Alzheimer's disease
KarXT
xanomeline
Flag link:
Eli Lilly (LLY) Tops Q2 Earnings and Revenue Estimates
Eli Lilly (LLY) Tops Q2 Earnings and Revenue Estimates
NASDAQ.com
Eli Lilly
earnings
Flag link:
Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease
Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease
Fierce Biotech
diabetes
Parkinson's Disease
GLP-1 agonist
AstraZeneca
Byetta
Bydureon
Novo Nordisk
Victoza
Ozempic
Eli Lilly
Trulicity
Peptron
Flag link:
Drugmaker Lilly plans IPO for part of animal health business
Drugmaker Lilly plans IPO for part of animal health business
Yahoo/AP
Eli Lilly
animal health
IPOs
Elanco
Flag link:
Anima, Eli Lilly pen $1B-plus biobucks research pact
Anima, Eli Lilly pen $1B-plus biobucks research pact
Fierce Biotech
Eli Lilly
Anima
biotech
translation inhibitors
drug development
Flag link:
Trajenta Meets Primary Endpoint in Cardiovascular Trial
Trajenta Meets Primary Endpoint in Cardiovascular Trial
CP Wire
Boehringer Ingelheim
Eli Lilly
Trajenta
Flag link:
Trajenta Meets Primary Endpoint in Cardiovascular Trial
Boehringer Ingelheim
Eli Lilly
Trajenta
Flag link:
Eli Lilly, Pfizer celebrate a PhIII success for their blockbuster pain drug contender tanezumab — but questions linger
Eli Lilly, Pfizer celebrate a PhIII success for their blockbuster pain drug contender tanezumab — but questions linger
Endpoints
Eli Lilly
Pfizer
anti-NGF
tanezumab
Flag link:
Lilly Oncology’s strategy? Listen to tough talk from patients—and save data for later
Lilly Oncology’s strategy? Listen to tough talk from patients—and save data for later
Fierce Pharma
Eli Lilly
oncology
patients
Flag link:
CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes
CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes
CP Wire
CHMP
Boehringer Ingelheim
Eli Lilly
EMA
Jardiance
Synjardy
Glyxambi
diabetes
Flag link:
CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes
Boehringer Ingelheim
Eli Lilly
Jardiance
Synjardy
Glyxambi
Flag link:
Touting PhIII success for arthritis drug Taltz, Eli Lilly chases rival Novartis in heated immunology race
Touting PhIII success for arthritis drug Taltz, Eli Lilly chases rival Novartis in heated immunology race
Endpoints
Eli Lilly
Taltz
Novartis
ankylosing spondylitis
Cosentyx
Flag link:
ADA: Lilly's Trulicity bests Novo's Victoza, AZ's Bydureon in real-world study
ADA: Lilly's Trulicity bests Novo's Victoza, AZ's Bydureon in real-world study
Fierce Pharma
Eli Lilly
Trulicity
diabetes
Novo Nordisk
Victoza
AstraZeneca
Bydureon
ADA
Flag link:
ADA: Lilly, BI's Jardiance cut kidney disease progression in Empa-Reg analysis
ADA: Lilly, BI's Jardiance cut kidney disease progression in Empa-Reg analysis
Fierce Pharma
ADA
kidney disease
Eli Lilly
Boehringer Ingelheim
Flag link:
5 Biggest Blockbuster Diabetes Drugs of the Future
5 Biggest Blockbuster Diabetes Drugs of the Future
Motley Fool
Eli Lilly
Trulicity
Novo Nordisk
Ozempic
Boehringer Ingelheim
Jardiance
Tresiba
NovoRapid
Flag link:
Merck & Co. could try to acquire Elanco (13.5bn)
Merck & Co. could try to acquire Elanco (13.5bn)
GoinPharma
Merck
animal health
Elanco
M&A
Eli Lilly
Flag link:

Pages